Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CTI BIOPHARMA CORPctic · Entity 111865 | Director | September 18, 2018 | September 20, 2018 |
| ORAGENICS INCOGEN · Entity 8495 | Director | December 11, 2025 | January 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CTI BIOPHARMA CORP
Report date September 18, 2018 · Filed September 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2028-09-18 | Direct | 60,000 |
Reported balance
After 2018-09-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-18 · Grant · Acquired 60,000 · Balance 60,000 F1: The option grant shall be fully vested and exercisable effective on the later of the Resignation Date or the effective date of the release as long as Dr. Telling remains in good standing on the Board with the Company through the Resignation Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant shall be fully vested and exercisable effective on the later of the Resignation Date or the effective date of the release as long as Dr. Telling remains in good standing on the Board with the Company through the Resignation Date.
ORAGENICS INC
Report date December 11, 2025 · Filed January 22, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 948 |
Reported balance
After 2025-12-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-12-12 · Sale · Disposed 210 · Balance 948 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.9440 to $0.9451. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F2: This Amendment is being filed to correct the amount of securities beneficially owned. The Issuer effected a 1-for-30 reverse stock split of its outstanding common stock, which was not reflected on the prior Form 4. |
| Non-Employee Director Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2035-12-11 | Direct | 125,000 |
Reported balance
After 2025-12-11 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2025-12-11 · Grant · Acquired 125,000 · Balance 125,000 F3: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.9440 to $0.9451. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2: This Amendment is being filed to correct the amount of securities beneficially owned. The Issuer effected a 1-for-30 reverse stock split of its outstanding common stock, which was not reflected on the prior Form 4.
F3: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2025 Filed Dec 15, 2025 21:38 UTC | ORAGENICS INC OGEN · Entity 8495 | SaleCommon Stock | 210 | $0.94 | $198.37 |
DisclosureSEC source: 0001382225-25-000002 · primary_doc.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,538 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.9440 to $0.9451. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 12, 2025 Filed Jan 22, 2026 18:04 UTC Amendment | ORAGENICS INC OGEN · Entity 8495 | SaleCommon Stock | 210 | $0.94 | $198.37 |
DisclosureSEC source: 0001382225-26-000001 · primary_doc.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 948 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.9440 to $0.9451. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F2 · balance_after: This Amendment is being filed to correct the amount of securities beneficially owned. The Issuer effected a 1-for-30 reverse stock split of its outstanding common stock, which was not reflected on the prior Form 4. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 21:38 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001382225-25-000002 · primary_doc.xml · derivative · entry 2 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-12-11 F2 · security: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F2 · shares: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F2 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F2 · balance_after: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
| December 11, 2025 Filed Jan 22, 2026 18:04 UTC Amendment | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001382225-26-000001 · primary_doc.xml · derivative · entry 2 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-12-11 F3 · shares: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F3 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F3 · balance_after: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 21:23 UTC | ORAGENICS INC OGEN · Entity 8495 | SaleCommon Stock | 3,597 | $0.36 | $1,294.92 |
DisclosureSEC source: 0001493152-24-049278 · ownership.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,748 Read SEC document |
| September 19, 2024 Filed Sep 21, 2024 01:15 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-24-037734 · ownership.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2034-09-19 F1 · security: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · shares: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · balance_after: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 22:23 UTC | ORAGENICS INC OGEN · Entity 8495 | SaleCommon Stock | 3,500 | $3.57 | $12,488.35 |
DisclosureSEC source: 0001493152-23-043456 · ownership.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,345 Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:30 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-027582 · ownership.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,845 F1 · shares: Represents an award of restricted stock pursuant to the Company's non-employee director compensation program under the Company's 2021 Equity Incentive Plan with 20,000 shares vesting immediately and 5,000 shares vesting in six (6) months. F2 · balance_after: Reflects adjustments made in connection with the 1-for-60 reverse stock split of the Issuer's common stock which became effective on January 23, 2023 Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 20:35 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 220,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001493152-22-021015 · ownership.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2032-07-29 F1 · security: Represents an award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2021 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, July 29, 2022. F1 · shares: Represents an award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2021 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, July 29, 2022. F1 · derivative.underlying_shares: Represents an award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2021 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, July 29, 2022. F1 · balance_after: Represents an award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2021 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, July 29, 2022. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:15 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001493152-22-017710 · ownership.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2022-06-23 F1 · security: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, in connection with service to the Company as Executive Chairman of the Board. The option vests immediately. The option exercise price is the closing price on the date of the grant, June 23, 2022. F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, in connection with service to the Company as Executive Chairman of the Board. The option vests immediately. The option exercise price is the closing price on the date of the grant, June 23, 2022. F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, in connection with service to the Company as Executive Chairman of the Board. The option vests immediately. The option exercise price is the closing price on the date of the grant, June 23, 2022. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:10 UTC Amendment | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001493152-22-017831 · ownership.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-06-23 F1 · security: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, in connection with service to the Company as Executive Chairman of the Board. The option vests immediately. The option exercise price is the closing price on the date of the grant, June 23, 2022. F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, in connection with service to the Company as Executive Chairman of the Board. The option vests immediately. The option exercise price is the closing price on the date of the grant, June 23, 2022. F2 · derivative.expiration_date: Due to a clerical error, the Form 4, as originally filed, incorrectly reported the option expiration date. The Form 4, as amended by this Form 4/A, correctly reports such information. No other changes have been made to the originally filed Form 4. F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, in connection with service to the Company as Executive Chairman of the Board. The option vests immediately. The option exercise price is the closing price on the date of the grant, June 23, 2022. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 13:30 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock | 10,084 | $0.29 | $2,884.02 |
DisclosureSEC source: 0001493152-22-017293 · ownership.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased at an average price of $0.2860 on June 17, 2022. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:05 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock | 78,673 | $0.29 | $22,775.83 |
DisclosureSEC source: 0001493152-22-015040 · ownership.xml · nonDerivative · entry 2 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 999,916 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging between $0.2800 and $0.3000 on May 24, 2022. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:05 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock | 3,500 | $0.29 | $1,004.15 |
DisclosureSEC source: 0001493152-22-015040 · ownership.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 921,243 Read SEC document |
| May 20, 2022 Filed May 23, 2022 20:15 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock | 65,718 | $0.28 | $18,637.62 |
DisclosureSEC source: 0001493152-22-014790 · ownership.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 917,743 Read SEC document |
| May 19, 2022 Filed May 20, 2022 20:15 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock | 56,806 | $0.28 | $15,945.44 |
DisclosureSEC source: 0001493152-22-014605 · ownership.xml · nonDerivative · entry 2 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,025 F1 · price: The prices reported in Column 4 are a weighted average prices. These shares were purchased in multiple transactions ranging between $0.2500 and $0.2700 on May 18, 2022 and between $0.2570 and $0.2998 on May 19, 2022. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:15 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock | 15,303 | $0.26 | $3,994.08 |
DisclosureSEC source: 0001493152-22-014605 · ownership.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,219 F1 · price: The prices reported in Column 4 are a weighted average prices. These shares were purchased in multiple transactions ranging between $0.2500 and $0.2700 on May 18, 2022 and between $0.2570 and $0.2998 on May 19, 2022. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 20:05 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock | 59,053 | $0.35 | $20,768.94 |
DisclosureSEC source: 0001493152-22-008799 · ownership.xml · nonDerivative · entry 2 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 779,916 F1 · price: The prices reported in Column 4 are a weighted average prices. These shares were purchased in multiple transactions ranging from $0.3510 to $0.3773 on March 30, 2022 and from $0.3407 to $0.3772 on March 31, 2022. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:05 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock | 124,785 | $0.36 | $45,284.48 |
DisclosureSEC source: 0001493152-22-008799 · ownership.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,863 F1 · price: The prices reported in Column 4 are a weighted average prices. These shares were purchased in multiple transactions ranging from $0.3510 to $0.3773 on March 30, 2022 and from $0.3407 to $0.3772 on March 31, 2022. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 22:07 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001493152-21-031890 · ownership.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-16 F1 · security: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, December 16, 2021. F1 · shares: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, December 16, 2021. F1 · derivative.underlying_shares: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, December 16, 2021. F1 · balance_after: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, December 16, 2021. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:06 UTC | ORAGENICS INC OGEN · Entity 8495 | Exercise / conversionNon-Employee Director Option (Right to Buy) · Derivative | 156,540 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-21-015714 · ownership.xml · derivative · entry 2 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 156,540 shares Expires 2029-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the exercise of a fully vested outstanding option award to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan. F1 · derivative.exercise_date: Represents the exercise of a fully vested outstanding option award to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:06 UTC | ORAGENICS INC OGEN · Entity 8495 | Exercise / conversionCommon Stock | 156,540 | $0.48 | $75,139.20 |
DisclosureSEC source: 0001493152-21-015714 · ownership.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:35 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001493152-21-004420 · ownership.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-02-18 F1 · security: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021. F1 · shares: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021. F1 · derivative.underlying_shares: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021. F1 · balance_after: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:05 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock | 100,000 | $0.37 | $37,000.00 |
DisclosureSEC source: 0001493152-20-022545 · ownership.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,538 F1 · price: Represents acquisition of shares of Common Stock through participation in the Company's underwritten public offering at the offering price per share of $0.37. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:30 UTC | ORAGENICS INC OGEN · Entity 8495 | OtherSeries 1 Common Stock Warrants (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001493152-20-009137 · ownership.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2020-05-14 F1 · security: Represents the expiration of an unexercised outstanding Warrant in accordance with its terms. F1 · shares: Represents the expiration of an unexercised outstanding Warrant in accordance with its terms. F1 · derivative.underlying_shares: Represents the expiration of an unexercised outstanding Warrant in accordance with its terms. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:15 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 156,540 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-20-001781 · ownership.xml · derivative · entry 2 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,540 Underlying: Common Stock · 156,540 shares Expires 2030-02-05 F2 · security: Represents a discretionary retention award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's Plan. The options vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 5, 2020. F2 · shares: Represents a discretionary retention award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's Plan. The options vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 5, 2020. F2 · derivative.underlying_shares: Represents a discretionary retention award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's Plan. The options vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 5, 2020. F2 · balance_after: Represents a discretionary retention award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's Plan. The options vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 5, 2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:15 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 156,540 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-20-001781 · ownership.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,540 Underlying: Common Stock · 156,540 shares Expires 2030-02-05 F1 · security: Represents an annual award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan") that vests immediately. F1 · shares: Represents an annual award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan") that vests immediately. F1 · derivative.underlying_shares: Represents an annual award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan") that vests immediately. F1 · balance_after: Represents an annual award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan") that vests immediately. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 21:05 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 156,540 | Not disclosed Strike: $0.48 | Not disclosed |
DisclosureSEC source: 0000899243-19-017958 · doc4.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,540 Underlying: Common Stock · 156,540 shares Expires 2029-06-20 F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a non-employee director. The option exercise price is the closing price on the date of the grant, June 20, 2019 (the "Grant Date"). The options vest quarterly in even amounts over the four quarters following the Grant Date. F1 · price: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a non-employee director. The option exercise price is the closing price on the date of the grant, June 20, 2019 (the "Grant Date"). The options vest quarterly in even amounts over the four quarters following the Grant Date. F1 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a non-employee director. The option exercise price is the closing price on the date of the grant, June 20, 2019 (the "Grant Date"). The options vest quarterly in even amounts over the four quarters following the Grant Date. F1 · derivative.underlying_shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a non-employee director. The option exercise price is the closing price on the date of the grant, June 20, 2019 (the "Grant Date"). The options vest quarterly in even amounts over the four quarters following the Grant Date. F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a non-employee director. The option exercise price is the closing price on the date of the grant, June 20, 2019 (the "Grant Date"). The options vest quarterly in even amounts over the four quarters following the Grant Date. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 20:05 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseSeries 2 Common Stock Warrants (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.90 | Not disclosed |
DisclosureSEC source: 0000899243-19-009014 · doc4.xml · derivative · entry 3 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2024-03-25 F1 · price: Purchase of Units consisting of one share of common stock and Series 1 Warrant to purchase one-half of a share of our Common Stock (exercisable through the earlier of 20 days post read out of AG013 clinical trial data or eighteen months) and a Series 2 Warrant to purchase one-half of a share of our Common Stock in an underwritten public offering at the price of $0.75 per Unit, which was the price paid by the public for such Units. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 20:05 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseSeries 1 Common Stock Warrants (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-19-009014 · doc4.xml · derivative · entry 2 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2020-09-25 F1 · price: Purchase of Units consisting of one share of common stock and Series 1 Warrant to purchase one-half of a share of our Common Stock (exercisable through the earlier of 20 days post read out of AG013 clinical trial data or eighteen months) and a Series 2 Warrant to purchase one-half of a share of our Common Stock in an underwritten public offering at the price of $0.75 per Unit, which was the price paid by the public for such Units. F1 · derivative.expiration_date: Purchase of Units consisting of one share of common stock and Series 1 Warrant to purchase one-half of a share of our Common Stock (exercisable through the earlier of 20 days post read out of AG013 clinical trial data or eighteen months) and a Series 2 Warrant to purchase one-half of a share of our Common Stock in an underwritten public offering at the price of $0.75 per Unit, which was the price paid by the public for such Units. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 20:05 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-009014 · doc4.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,538 F1 · price: Purchase of Units consisting of one share of common stock and Series 1 Warrant to purchase one-half of a share of our Common Stock (exercisable through the earlier of 20 days post read out of AG013 clinical trial data or eighteen months) and a Series 2 Warrant to purchase one-half of a share of our Common Stock in an underwritten public offering at the price of $0.75 per Unit, which was the price paid by the public for such Units. Read SEC document |
| September 27, 2018 Filed Oct 1, 2018 20:05 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000899243-18-025656 · doc4.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-09-27 F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended in connection with service to the Company as a director. The options vest immediately. The option exercise price is the closing price on the date of the grant, September 27, 2018. F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended in connection with service to the Company as a director. The options vest immediately. The option exercise price is the closing price on the date of the grant, September 27, 2018. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 16:23 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000891293-18-000085 · primary_doc.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-09-18 F1 · derivative.exercise_date: The option grant shall be fully vested and exercisable effective on the later of the Resignation Date or the effective date of the release as long as Dr. Telling remains in good standing on the Board with the Company through the Resignation Date. Read SEC document |
| July 17, 2018 Filed Jul 17, 2018 20:44 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 100,000 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0000899243-18-019954 · doc4.xml · derivative · entry 2 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2025-07-17 F1 · price: Purchase of Class A Units consisting of one share of common stock and one warrant to purchase one share of common stock in an underwritten public offering at the price of $1.00 per Unit, which was the price paid by the public for such Units. Read SEC document |
| July 17, 2018 Filed Jul 17, 2018 20:44 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-019954 · doc4.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,538 F1 · price: Purchase of Class A Units consisting of one share of common stock and one warrant to purchase one share of common stock in an underwritten public offering at the price of $1.00 per Unit, which was the price paid by the public for such Units. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 20:17 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0000899243-18-018136 · doc4.xml · derivative · entry 2 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-06-22 F2 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a director. The options vest one year from the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2018. F2 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a director. The options vest one year from the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2018. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 20:17 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-018136 · doc4.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,538 F1 · shares: Represents an award of restricted stock in connection with service to the Company as a director pursuant to the 2012 Equity Incentive Plan that vests immediately. Read SEC document |
| May 17, 2018 Filed May 17, 2018 18:20 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000891293-18-000061 · primary_doc.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: This stock option was granted on May 17, 2018 and vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2019 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 19:27 UTC | ORAGENICS INC OGEN.BC · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0000899243-17-017198 · doc4.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2027-06-22 F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a director. The options vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2017 F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a director. The options vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2017 Read SEC document |
| April 29, 2017 Filed May 2, 2017 17:46 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionRestricted Stock Unit · Derivative | 34,736 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-011488 · doc4.xml · derivative · entry 2 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of CTIC common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · shares: CTIC completed a 1-for-10 reverse stock split in January 2017. All share amounts reported in this Form 4 have been retroactively adjusted to reflect this stock split. F3 · derivative.exercise_date: This restricted stock unit was granted on April 29, 2016 and vested on April 29, 2017. F3 · derivative.expiration_date: This restricted stock unit was granted on April 29, 2016 and vested on April 29, 2017. F1 · derivative.underlying_shares: CTIC completed a 1-for-10 reverse stock split in January 2017. All share amounts reported in this Form 4 have been retroactively adjusted to reflect this stock split. Read SEC document |
| April 29, 2017 Filed May 2, 2017 17:46 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionCommon Stock | 34,736 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-011488 · doc4.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: CTIC completed a 1-for-10 reverse stock split in January 2017. All share amounts reported in this Form 4 have been retroactively adjusted to reflect this stock split. F2 · price: Each restricted stock unit represents the right to receive, at settlement, one share of CTIC common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 17:33 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0000899243-17-005430 · doc4.xml · derivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-02-22 F1 · derivative.exercise_date: This stock option was granted on February 23, 2017 and vests on the first to occur of (i) the date that is twelve months after the date of grant, (ii) the first annual meeting of CTIC's shareholders in 2018 at which one or more members of the CTIC Board of Directors are to be elected, or (iii) immediately prior to the occurrence of a Change of Control (as such term is defined in CTIC's 2015 Equity Incentive Plan), subject to the Reporting Persons' continued service through such date or event. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:05 UTC | ORAGENICS INC OGEN.BC · Entity 8495 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003780 · doc4.xml · nonDerivative · entry 1 Telling Fred · CIK 0001382225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,355,354 F1 · shares: Represents an award of restricted stock in connection with service to the Company as a director pursuant to the 2012 Equity Incentive Plan that vest equally over each of the four calendar quarters during 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.